Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID	DTD0391 Transporter Info
Gene Name	SLC51A
Transporter Name	Organic solute transporter subunit alpha
Gene ID	200931
UniProt ID	Q86UW1

Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)
Chemical Compound
DT Modulation1	Valproic Acid affects the expression of SLC51A mRNA		[53]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	Calcitriol co-treated with Chenodeoxycholic Acid results in decreased expression of SLC51A mRNA		[4]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	Fidaxomicin inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Glycochenodeoxycholic Acid		[44]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Fidaxomicin inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Glycocholic Acid		[44]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Fidaxomicin inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Taurochenodeoxycholic Acid		[44]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	Fidaxomicin inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Taurocholic Acid		[44]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	Benzo(a)pyrene results in decreased methylation of SLC51A exon		[35]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Benzo(a)pyrene results in decreased methylation of SLC51A promoter		[35]
Regulation Mechanism			Transcription Factor Info
7-hydroxytheonellasterol	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	7-hydroxytheonellasterol inhibits the reaction Chenodeoxycholic Acid inhibits the reaction NCOR1 protein binds to SLC51A promoter		[29]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	7-hydroxytheonellasterol inhibits the reaction Chenodeoxycholic Acid results in increased expression of SLC51A mRNA		[29]
Regulation Mechanism			Transcription Factor Info
8-Bromo Cyclic Adenosine Monophosphate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	8-Bromo Cyclic Adenosine Monophosphate results in increased expression of SLC51A mRNA		[30]
Regulation Mechanism			Transcription Factor Info
Amoxicillin-Potassium Clavulanate Combination	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Amoxicillin-Potassium Clavulanate Combination results in decreased expression of SLC51A mRNA		[18]
Regulation Mechanism			Transcription Factor Info
Atazanavir Sulfate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[33]
Regulation Mechanism			Transcription Factor Info
azoxystrobin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	azoxystrobin results in decreased expression of SLC51A mRNA		[34]
Regulation Mechanism			Transcription Factor Info
benzo(e)pyrene	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	benzo(e)pyrene results in decreased methylation of SLC51A intron		[31]
Regulation Mechanism			Transcription Factor Info
bisphenol A	4 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	bisphenol A affects the expression of SLC51A mRNA		[36]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	bisphenol A co-treated with Fulvestrant results in increased methylation of SLC51A gene		[37]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	bisphenol A results in decreased methylation of SLC51A gene		[37]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	bisphenol A results in increased expression of SLC51A mRNA		[25]
Regulation Mechanism			Transcription Factor Info
Chenodeoxycholic Acid	16 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[38]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	7-hydroxytheonellasterol inhibits the reaction Chenodeoxycholic Acid inhibits the reaction NCOR1 protein binds to SLC51A promoter		[29]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	7-hydroxytheonellasterol inhibits the reaction Chenodeoxycholic Acid results in increased expression of SLC51A mRNA		[29]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation5	Calcitriol co-treated with Chenodeoxycholic Acid results in decreased expression of SLC51A mRNA		[4]
Regulation Mechanism			Transcription Factor Info
DT Modulation6	Chenodeoxycholic Acid inhibits the reaction NCOR1 protein binds to SLC51A promoter		[29]
Regulation Mechanism			Transcription Factor Info
DT Modulation7	Chenodeoxycholic Acid promotes the reaction Oxygen deficiency results in increased expression of SLC51A mRNA		[2]
Regulation Mechanism			Transcription Factor Info
DT Modulation8	Chenodeoxycholic Acid results in increased expression of SLC51A mRNA		[39]
Regulation Mechanism			Transcription Factor Info
DT Modulation9	Chenodeoxycholic Acid results in increased expression of SLC51A protein		[39]
Regulation Mechanism			Transcription Factor Info
DT Modulation10	epigallocatechin gallate inhibits the reaction Chenodeoxycholic Acid results in increased expression of SLC51A mRNA		[40]
Regulation Mechanism			Transcription Factor Info
DT Modulation11	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation12	HIF1A mutant form inhibits the reaction Chenodeoxycholic Acid results in increased expression of SLC51A mRNA		[2]
Regulation Mechanism			Transcription Factor Info
DT Modulation13	NR1H4 mutant form inhibits the reaction Chenodeoxycholic Acid results in increased expression of SLC51A mRNA		[2]
Regulation Mechanism			Transcription Factor Info
DT Modulation14	NR1H4 protein affects the reaction Chenodeoxycholic Acid results in increased expression of SLC51A mRNA		[39]
Regulation Mechanism			Transcription Factor Info
DT Modulation15	Oxygen deficiency promotes the reaction Chenodeoxycholic Acid results in increased expression of SLC51A mRNA		[2]
Regulation Mechanism			Transcription Factor Info
DT Modulation16	Triclosan co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[38]
Regulation Mechanism			Transcription Factor Info
chlortoluron	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	chlortoluron results in decreased expression of SLC51A mRNA		[34]
Regulation Mechanism			Transcription Factor Info
Cisplatin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	SLC51A results in increased susceptibility to Cisplatin		[41]
Regulation Mechanism			Transcription Factor Info
Clavulanic Acid	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Clavulanic Acid inhibits the reaction GW 4064 results in increased expression of SLC51A mRNA		[18]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Clavulanic Acid results in decreased expression of SLC51A mRNA		[18]
Regulation Mechanism			Transcription Factor Info
cyproconazole	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	cyproconazole results in decreased expression of SLC51A mRNA		[34]
Regulation Mechanism			Transcription Factor Info
Deoxycholic Acid	6 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[38]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Deoxycholic Acid results in increased expression of SLC51A		[42]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	Deoxycholic Acid results in increased expression of SLC51A mRNA		[7]
Regulation Mechanism			Transcription Factor Info
DT Modulation5	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation6	Triclosan co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[38]
Regulation Mechanism			Transcription Factor Info
deoxynivalenol	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	deoxynivalenol results in decreased expression of SLC51A mRNA		[28]
Regulation Mechanism			Transcription Factor Info
di-n-butylphosphoric acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	di-n-butylphosphoric acid affects the expression of SLC51A mRNA		[43]
Regulation Mechanism			Transcription Factor Info
epigallocatechin gallate	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	epigallocatechin gallate inhibits the reaction Chenodeoxycholic Acid results in increased expression of SLC51A mRNA		[40]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	epigallocatechin gallate inhibits the reaction GW 4064 results in increased expression of SLC51A mRNA		[40]
Regulation Mechanism			Transcription Factor Info
fluxapyroxad	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	fluxapyroxad results in decreased expression of SLC51A mRNA		[34]
Regulation Mechanism			Transcription Factor Info
Fulvestrant	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	bisphenol A co-treated with Fulvestrant results in increased methylation of SLC51A gene		[37]
Regulation Mechanism			Transcription Factor Info
Glycochenodeoxycholic Acid	7 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[38]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Fidaxomicin inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Glycochenodeoxycholic Acid		[44]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation5	SLC51A protein binds to SLC51B protein which results in increased uptake of Glycochenodeoxycholic Acid		[44]
Regulation Mechanism			Transcription Factor Info
DT Modulation6	Triclosan co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[38]
Regulation Mechanism			Transcription Factor Info
DT Modulation7	troglitazone sulfate inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Glycochenodeoxycholic Acid		[44]
Regulation Mechanism			Transcription Factor Info
Glycocholic Acid	6 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[38]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Fidaxomicin inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Glycocholic Acid		[44]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation5	SLC51A protein binds to SLC51B protein which results in increased uptake of Glycocholic Acid		[44]
Regulation Mechanism			Transcription Factor Info
DT Modulation6	Triclosan co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[38]
Regulation Mechanism			Transcription Factor Info
Glycodeoxycholic Acid	4 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[38]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	Triclosan co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[38]
Regulation Mechanism			Transcription Factor Info
GW 4064	3 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Clavulanic Acid inhibits the reaction GW 4064 results in increased expression of SLC51A mRNA		[18]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	epigallocatechin gallate inhibits the reaction GW 4064 results in increased expression of SLC51A mRNA		[40]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	GW 4064 results in increased expression of SLC51A mRNA		[40]
Regulation Mechanism			Transcription Factor Info
Methapyrilene	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Methapyrilene results in decreased methylation of SLC51A intron		[31]
Regulation Mechanism			Transcription Factor Info
methyleugenol	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	methyleugenol results in decreased expression of SLC51A mRNA		[26]
Regulation Mechanism			Transcription Factor Info
NCS 382	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	NCS 382 results in decreased expression of SLC51A mRNA		[45]
Regulation Mechanism			Transcription Factor Info
N-Nitrosopyrrolidine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	N-Nitrosopyrrolidine results in decreased expression of SLC51A mRNA		[26]
Regulation Mechanism			Transcription Factor Info
obeticholic acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	obeticholic acid results in increased expression of SLC51A mRNA		[12]
Regulation Mechanism			Transcription Factor Info
Okadaic Acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Okadaic Acid results in decreased expression of SLC51A mRNA		[47]
Regulation Mechanism			Transcription Factor Info
Oxygen	5 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Chenodeoxycholic Acid promotes the reaction Oxygen deficiency results in increased expression of SLC51A mRNA		[2]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	HIF1A mutant form inhibits the reaction Oxygen deficiency results in increased expression of SLC51A mRNA		[2]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Oxygen deficiency promotes the reaction Chenodeoxycholic Acid results in increased expression of SLC51A mRNA		[2]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	Oxygen deficiency results in increased expression of SLC51A mRNA		[2]
Regulation Mechanism			Transcription Factor Info
DT Modulation5	Oxygen deficiency results in increased expression of SLC51A protein		[2]
Regulation Mechanism			Transcription Factor Info
perfluorobutanesulfonic acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	SLC51A protein binds to SLC51B protein which results in increased transport of perfluorobutanesulfonic acid		[48]
Regulation Mechanism			Transcription Factor Info
perfluorohexanesulfonic acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	SLC51A protein binds to SLC51B protein which results in increased transport of perfluorohexanesulfonic acid		[48]
Regulation Mechanism			Transcription Factor Info
perfluorooctane sulfonic acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	SLC51A protein binds to SLC51B protein which results in increased transport of perfluorooctane sulfonic acid		[48]
Regulation Mechanism			Transcription Factor Info
propiconazole	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	propiconazole results in decreased expression of SLC51A mRNA		[49]
Regulation Mechanism			Transcription Factor Info
sodium arsenite	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	sodium arsenite results in increased abundance of Arsenic which results in increased expression of SLC51A mRNA		[32]
Regulation Mechanism			Transcription Factor Info
sulforaphane	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	sulforaphane results in decreased expression of SLC51A mRNA		[18]
Regulation Mechanism			Transcription Factor Info
Taurochenodeoxycholic Acid	3 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Fidaxomicin inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Taurochenodeoxycholic Acid		[44]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	SLC51A protein binds to SLC51B protein which results in increased uptake of Taurochenodeoxycholic Acid		[44]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	troglitazone sulfate inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Taurochenodeoxycholic Acid		[44]
Regulation Mechanism			Transcription Factor Info
Taurocholic Acid	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Fidaxomicin inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Taurocholic Acid		[44]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	SLC51A protein binds to SLC51B protein which results in increased uptake of Taurocholic Acid		[44]
Regulation Mechanism			Transcription Factor Info
Triclosan	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Triclosan co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51A mRNA		[38]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Triclosan results in decreased expression of SLC51A mRNA		[51]
Regulation Mechanism			Transcription Factor Info
triphenyl phosphate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	triphenyl phosphate affects the expression of SLC51A mRNA		[43]
Regulation Mechanism			Transcription Factor Info
tris(2-butoxyethyl) phosphate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	tris(2-butoxyethyl) phosphate affects the expression of SLC51A mRNA		[52]
Regulation Mechanism			Transcription Factor Info
troglitazone sulfate	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	troglitazone sulfate inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Glycochenodeoxycholic Acid		[44]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	troglitazone sulfate inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Taurochenodeoxycholic Acid		[44]
Regulation Mechanism			Transcription Factor Info
Fungicide
tebuconazole	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	tebuconazole results in decreased expression of SLC51A mRNA		[49]
Regulation Mechanism			Transcription Factor Info
Approved Drug
Cholic Acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Cholic Acid increases the expression of SLC51A		[1]
Regulation Mechanism	via enhancement of Bile acid receptor (NR1H4)		Transcription Factor Info
Cell System	Mouse colon adenocarcinoma cells (CT26)
Deoxycholic acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Deoxycholic acid increases the expression of SLC51A		[2]
Regulation Mechanism	via enhancement of Bile acid receptor (NR1H4)		Transcription Factor Info
Cell System	Human adult hepatocellular carcinoma cells (Huh7)
Chenodeoxycholic acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Chenodeoxycholic acid increases the expression of SLC51A		[2]
Regulation Mechanism	via enhancement of Bile acid receptor (NR1H4)		Transcription Factor Info
Cell System	Human adult hepatocellular carcinoma cells (Huh7)
Copper Sulfate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Copper Sulfate inhibits the expression of SLC51A		[3]
Budesonide	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Budesonide increases the expression of SLC51A		[4]
Dexamethasone	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Dexamethasone affects the expression of SLC51A		[4]
Hydrogen Peroxide	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Hydrogen Peroxide affects the expression of SLC51A		[5]
Methotrexate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Methotrexate increases the expression of SLC51A		[6]
Ursodeoxycholic Acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Ursodeoxycholic Acid increases the expression of SLC51A		[7]
Rosiglitazone	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Rosiglitazone inhibits the expression of SLC51A		[8]
Ritonavir	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Ritonavir inhibits the expression of SLC51A		[9]
Acetaminophen	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Acetaminophen inhibits the expression of SLC51A		[10]
Rifampin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Rifampin increases the expression of SLC51A		[11]
Obeticholic acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Obeticholic acid increases the expression of SLC51A		[12]
Urethane	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Urethane inhibits the expression of SLC51A		[13]
Leflunomide	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Leflunomide increases the expression of SLC51A		[14]
Valproic Acid	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Valproic Acid inhibits the expression of SLC51A		[15]
Bosentan	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Bosentan increases the expression of SLC51A		[16]
Tretinoin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Tretinoin increases the expression of SLC51A		[17]
Amoxicillin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Amoxicillin increases the expression of SLC51A		[18]
Phenobarbital	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Phenobarbital increases the expression of SLC51A		[19]
Calcitriol	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Calcitriol inhibits the expression of SLC51A		[4]
Cyclosporine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Cyclosporine inhibits the expression of SLC51A		[20]
Fidaxomicin	5 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Fidaxomicin inhibits the activity of SLC51A		[21]
Troglitazone	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Troglitazone inhibits the activity of SLC51A		[21]
Drug in Phase 3 Trial
Sulforafan	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Sulforafan inhibits the expression of SLC51A		[18]
Drug in Phase 2 Trial
Bisphenol A	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Bisphenol A increases the expression of SLC51A		[25]
Drug in Phase 1 Trial
Quercetin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Quercetin inhibits the expression of SLC51A		[23]
Investigative Drug
Lithocholic Acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Lithocholic Acid increases the expression of SLC51A		[4]
Regulation Mechanism	via enhancement of Bile acid receptor (NR1H4)		Transcription Factor Info
Cell System	Human liver cells
Patented Pharmaceutical Agent
GW-4064	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	GW-4064 increases the expression of SLC51A		[22]
Regulation Mechanism	via enhancement of Bile acid receptor (NR1H4)		Transcription Factor Info
Cell System	Human adrenal cortex carcinoma cells (H295R)
Natural Product
Methyleugenol	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Methyleugenol inhibits the expression of SLC51A		[26]
Resveratrol	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Plant Extracts co-treated with Resveratrol results in decreased expression of SLC51A mRNA		[50]
Regulation Mechanism			Transcription Factor Info
Mycotoxins
Aflatoxin B1	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Aflatoxin B1 inhibits the expression of SLC51A		[24]
DT Modulation2	Aflatoxin B1 results in decreased methylation of SLC51A intron		[31]
Regulation Mechanism			Transcription Factor Info
Deoxynivalenol	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Deoxynivalenol inhibits the expression of SLC51A		[28]
Acute Toxic Substance
Oxyquinoline	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Oxyquinoline inhibits the expression of SLC51A		[23]
Acrylamide	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Acrylamide increases the expression of SLC51A		[27]
Carcinogen
Benzo(a)pyrene	3 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Benzo(a)pyrene inhibits the expression of SLC51A		[26]
Arsenic	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	sodium arsenite results in increased abundance of Arsenic which results in increased expression of SLC51A mRNA		[32]
Regulation Mechanism			Transcription Factor Info
Nickel	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Nickel results in increased expression of SLC51A mRNA		[46]
Regulation Mechanism			Transcription Factor Info

References
1	Regulation of the mouse organic solute transporter alpha-beta, Ostalpha-Ostbeta, by bile acids. Am J Physiol Gastrointest Liver Physiol. 2006 May;290(5):G912-22.
2	The organic solute transporters alpha and beta are induced by hypoxia in human hepatocytes. Liver Int. 2015 Apr;35(4):1152-61.
3	Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
4	Expression and regulation of the bile acid transporter, OSTalpha-OSTbeta in rat and human intestine and liver. Biopharm Drug Dispos. 2009 Jul;30(5):241-58.
5	Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203.
6	Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
7	Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46.
8	Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
9	Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016 Aug 5;255:31-44.
10	Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
11	Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
12	Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
13	Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
14	Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
15	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
16	Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
17	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423.
18	Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664.
19	Proteomic analysis of hepatic effects of phenobarbital in mice with humanized liver. Arch Toxicol. 2022 Oct;96(10):2739-2754.
20	Integrative "-Omics" Analysis in Primary Human Hepatocytes Unravels Persistent Mechanisms of Cyclosporine A-Induced Cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
21	Organic solute transporter OST/ is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury. Am J Physiol Gastrointest Liver Physiol. 2018 May 1;314(5):G597-G609.
22	FXR regulates organic solute transporters alpha and beta in the adrenal gland, kidney, and intestine. J Lipid Res. 2006 Jan;47(1):201-14.
23	Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
24	Aflatoxin B1 induces persistent epigenomic effects in primary human hepatocytes associated with hepatocellular carcinoma. Toxicology. 2016 Mar 28;350-352:31-9.
25	Comparison of transcriptome expression alterations by chronic exposure to low-dose bisphenol A in different subtypes of breast cancer cells. Toxicol Appl Pharmacol. 2019 Dec 15;385:114814.
26	Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297.
27	Acrylamide exposure represses neuronal differentiation, induces cell apoptosis and promotes tau hyperphosphorylation in hESC-derived 3D cerebral organoids. Food Chem Toxicol. 2020 Oct;144:111643.
28	Exposure to the mycotoxin deoxynivalenol reduces the transport of conjugated bile acids by intestinal Caco-2 cells. Arch Toxicol. 2022 May;96(5):1473-1482.
29	Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. PLoS One. 2012;7(1):e30443.
30	Mechanistic profiling of the cAMP-dependent steroidogenic pathway in the H295R endocrine disrupter screening system: new endpoints for toxicity testing. Toxicol Lett. 2012;208(2):174-84.
31	Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018;121:214-223.
32	Using transcriptomic signatures to elucidate individual and mixture effects of inorganic arsenic and manganese in human placental trophoblast HTR-8/SVneo cells. Toxicol Sci. 2025;203(2):216-226.
33	Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172.
34	Comparative case study on NAMs: towards enhancing specific target organ toxicity analysis. Arch Toxicol. 2024;98(11):3641-3658.
35	Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017;8(1):1369-1391.
36	Comprehensive analysis of transcriptomic changes induced by low and high doses of bisphenol A in HepG2 spheroids in vitro and rat liver in vivo. Environ Res. 2019 Jun;173:124-134.
37	DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019;11(1):138.
38	Dataset on transcriptomic profiling of cholestatic liver injury induced by food additives and a cosmetic ingredient. Data Brief. 2021;38:107373.
39	Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol. 2006 Jun;290(6):G1124-30.
40	A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor. Toxicol Appl Pharmacol. 2012 Jan 15;258(2):268-74.
41	Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS One. 2011;6(7):e21920.
42	Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys. Toxicol Sci. 2012 Apr;126(2):446-56.
43	Association between Organophosphate Ester Exposure and Insulin Resistance with Glycometabolic Disorders among Older Chinese Adults 60-69 Years of Age: Evidence from the China BAPE Study. Environ Health Perspect. 2023;131(4):47009.
44	Role of Organic Solute Transporter Alpha/Beta in Hepatotoxic Bile Acid Transport and Drug Interactions. Toxicol Sci. 2020;176(1):34-35.
45	In vitro toxicological evaluation of NCS-382, a high-affinity antagonist of hydroxybutyrate (GHB) binding. Toxicol In Vitro. 2017;40:196-202.
46	Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. J Allergy Clin Immunol. 2014;134(2):362-72.
47	A multi-omics approach to elucidate okadaic acid-induced changes in human HepaRG hepatocarcinoma cells. Arch Toxicol. 2024;98(9):2919-2935.
48	Na+/Taurocholate Cotransporting Polypeptide and Apical Sodium-Dependent Bile Acid Transporter Are Involved in the Disposition of Perfluoroalkyl Sulfonates in Humans and Rats. Toxicol Sci. 2015;146(2):363-73.
49	New Approach Methods for Hazard Identification: A Case Study with Azole Fungicides Affecting Molecular Targets Associated with the Adverse Outcome Pathway for Cholestasis. Cells. 2022;11(20).
50	One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol Res. 2013;72:69-82.
51	Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals. Int J Mol Sci. 2021;22(20).
52	Toxicogenomics of the flame retardant tris (2-butoxyethyl) phosphate in HepG2 cells using RNA-seq. Toxicol In Vitro. 2018;46:178-188.
53	Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.

Detail Information of Exogenous Modulation

Visitor Map

Correspondence